PUBLISHER: Fairfield Market Research | PRODUCT CODE: 2079613
PUBLISHER: Fairfield Market Research | PRODUCT CODE: 2079613
PD-L1 Biomarker Testing Market Insights, Competitive Landscape, and Market Forecast - 2033
The global PD-L1 biomarker testing market is experiencing steady growth as precision medicine becomes increasingly important in modern oncology. The rising adoption of personalized cancer treatment strategies, growing prevalence of various cancers, and expanding use of immune checkpoint inhibitors are driving demand for reliable biomarker testing solutions worldwide. PD-L1 testing has become a critical diagnostic tool for identifying patients who are most likely to benefit from immunotherapy, enabling healthcare providers to improve treatment outcomes while supporting more informed clinical decision-making.
The global PD-L1 biomarker testing market is expected to be valued at US$ 840.10 Million in 2026 and is projected to reach US$ 1,468.01 Million by 2033, growing at a CAGR of 8.3% between 2026 and 2033. The increasing integration of companion diagnostics into cancer treatment pathways, continuous technological advancements, and expanding research in immuno-oncology continue to strengthen the market's long-term growth prospects across developed and emerging healthcare markets.
Market Insights
The PD-L1 biomarker testing market has become an integral part of cancer diagnostics as healthcare providers increasingly adopt precision medicine approaches for personalized treatment planning. The growing use of immunotherapies across multiple cancer indications has significantly increased the need for accurate and standardized biomarker testing. Healthcare institutions are investing in advanced laboratory technologies that improve diagnostic accuracy, reduce turnaround times, and enhance workflow efficiency.
Technological advancements have improved the sensitivity, specificity, and reproducibility of PD-L1 testing, enabling laboratories to deliver consistent and reliable results. Continuous improvements in immunohistochemistry assays, molecular diagnostic platforms, and next-generation sequencing technologies are supporting more comprehensive biomarker analysis. Growing awareness among clinicians regarding the clinical value of biomarker-guided therapies is also contributing to increased testing volumes worldwide.
Market Drivers
One of the major drivers supporting market expansion is the increasing global incidence of cancer, particularly non-small cell lung cancer, melanoma, renal cell carcinoma, and several other malignancies where immunotherapy has demonstrated significant clinical benefits. As patient populations continue to grow, demand for biomarker testing prior to treatment initiation is expanding accordingly.
The rapid advancement of immuno-oncology therapies is another key growth factor. Pharmaceutical companies are developing innovative immune checkpoint inhibitors that require companion diagnostic testing to identify eligible patients, creating sustained demand for PD-L1 biomarker testing across healthcare systems.
Increasing regulatory support for companion diagnostics and the expanding number of approved immunotherapy drugs are also encouraging wider adoption of PD-L1 testing. In addition, growing investments in oncology research, clinical trials, and biomarker discovery continue to enhance the role of PD-L1 testing in routine clinical practice.
Business Opportunity
The market offers substantial opportunities as healthcare providers increasingly focus on personalized medicine and targeted treatment strategies. The integration of artificial intelligence, digital pathology, and automated image analysis into diagnostic workflows is expected to improve testing efficiency while minimizing interpretation variability.
Liquid biopsy technologies represent an emerging opportunity by providing less invasive alternatives for biomarker assessment. Continuous innovation in molecular diagnostics and next-generation sequencing is expected to broaden the scope of PD-L1 testing while supporting comprehensive genomic profiling for cancer patients.
Expanding healthcare infrastructure across emerging economies, rising cancer screening initiatives, and increasing availability of advanced diagnostic laboratories are creating new opportunities for market participants. Strategic collaborations among diagnostic manufacturers, pharmaceutical companies, and research institutions are also expected to accelerate product development and expand global market penetration.
Regional Analysis
North America continues to maintain a leading position in the global PD-L1 biomarker testing market owing to its advanced healthcare infrastructure, widespread adoption of precision medicine, strong presence of leading biotechnology companies, and increasing use of companion diagnostics in oncology treatment protocols. The region also benefits from significant research funding and favorable regulatory support for innovative cancer diagnostics.
Europe represents a significant market driven by growing cancer awareness, increasing implementation of personalized medicine initiatives, and strong investments in clinical research. Expanding access to advanced diagnostic technologies and supportive healthcare policies continue to encourage market growth throughout the region.
East Asia is emerging as one of the fastest-growing regional markets due to increasing cancer incidence, expanding healthcare investments, rapid adoption of advanced diagnostic technologies, and growing pharmaceutical research activities. Rising demand for precision oncology is further supporting regional expansion.
South Asia & Oceania is witnessing steady market growth fueled by improving healthcare infrastructure, increasing availability of specialized oncology centers, and greater awareness regarding early cancer diagnosis. Government initiatives supporting cancer care are also contributing to increased adoption of biomarker testing.
Latin America is gradually strengthening its market position as healthcare providers expand access to advanced diagnostic services and personalized cancer treatment. Continued investments in laboratory modernization and oncology care are expected to support future growth.
The Middle East & Africa is experiencing growing demand as healthcare systems continue to improve cancer diagnosis capabilities, expand specialized treatment facilities, and increase investments in modern diagnostic technologies.
Competitive Landscape
The global PD-L1 biomarker testing market remains highly competitive, with leading companies focusing on technological innovation, product development, strategic collaborations, and regulatory approvals to strengthen their market positions. Manufacturers are investing in advanced diagnostic platforms that offer improved accuracy, standardized testing procedures, and enhanced laboratory efficiency. Partnerships between pharmaceutical companies and diagnostic developers continue to support the expansion of companion diagnostics for emerging immunotherapy treatments. Continuous research aimed at improving biomarker identification and clinical validation is expected to further enhance market competitiveness throughout the forecast period.
Companies Covered in the PD-L1 Biomarker Testing Market
- F. Hoffmann-La Roche Ltd.
- Agilent Technologies, Inc.
- Merck and Co., Inc.
- Bristol-Myers Squibb
- Thermo Fisher Scientific
- Abcam plc.
- Abbott Laboratories
- Illumina, Inc.
- Guardant Health, Inc.
- Foundation Medicine, Inc.
- Danaher Corporation (Leica Biosystems)
- Bio-Techne Corporation
- Cell Signaling Technology, Inc.
- Sysmex Corporation
- Innovent Biologics, Inc.
Future Outlook
The PD-L1 biomarker testing market is expected to witness sustained expansion throughout the forecast period as precision oncology continues to transform cancer diagnosis and treatment. Increasing adoption of companion diagnostics, continuous innovation in molecular testing technologies, and expanding applications of immunotherapy are expected to drive long-term market growth. Greater integration of digital pathology, artificial intelligence, and minimally invasive diagnostic approaches will further improve testing capabilities and clinical outcomes. Companies that continue investing in innovation, strategic partnerships, and global market expansion are expected to strengthen their competitive positions while addressing the growing demand for personalized cancer care.
Market Segmentation
By Test Type
- Non-Small Cell Lung Cancer NSCLC
- Melanoma
- Renal Cell Carcinoma
- Gastrointestinal Tract Malignancy
- Haematological Malignancies
- Ovarian Cancer
- Other
By Technology
- Immunohistochemistry IHC Based Testing
- Polymerase Chain Reaction Based Testing
- Next Generation Sequencing Based Testing
By Sample Type
- Tissue Biopsy Samples
- Blood Based Liquid Biopsy
Regions
- North America
- Europe
- East Asia
- South Asia & Oceania
- Latin America
- Middle East & Africa
Table of Contents
1. Executive Summary
- 1.1. Global PD-L1 Biomarker Testing Market Snapshot
- 1.2. Future Projections
- 1.3. Key Market Trends
- 1.4. Regional Snapshot, by Value, 2026
- 1.5. Analyst Recommendations
2. Market Overview
- 2.1. Market Definitions and Segmentations
- 2.2. Market Dynamics
- 2.2.1. Drivers
- 2.2.2. Restraints
- 2.2.3. Market Opportunities
- 2.3. Value Chain Analysis
- 2.4. COVID-19 Impact Analysis
- 2.5. Porter's Five Forces Analysis
- 2.6. Impact of Russia-Ukraine Conflict
- 2.7. PESTLE Analysis
- 2.8. Regulatory Analysis
- 2.9. Price Trend Analysis
- 2.9.1. Current Prices and Future Projections, 2025-2033
- 2.9.2. Price Impact Factors
3. Global PD-L1 Biomarker Testing Market Outlook, 2020-2033
- 3.1. Global PD-L1 Biomarker Testing Market Outlook, by Test Type, Value (US$ Mn), 2020-2033
- 3.1.1. Non-Small Cell Lung Cancer NSCLC
- 3.1.2. Melanoma
- 3.1.3. Renal Cell Carcinoma
- 3.1.4. Gastrointestinal Tract Malignancy
- 3.1.5. Haematological Malignancies
- 3.1.6. Ovarian Cancer
- 3.1.7. Other
- 3.2. Global PD-L1 Biomarker Testing Market Outlook, by Technology, Value (US$ Mn), 2020-2033
- 3.2.1. Immunohistochemistry IHC Based Testing
- 3.2.2. Polymerase Chain Reaction Based Testing
- 3.2.3. Next Generation Sequencing Based Testing
- 3.2.4. Others
- 3.3. Global PD-L1 Biomarker Testing Market Outlook, by Sample Type, Value (US$ Mn), 2020-2033
- 3.3.1. Tissue Biopsy Samples
- 3.3.2. Blood Based Liquid Biopsy
- 3.4. Global PD-L1 Biomarker Testing Market Outlook, by Region, Value (US$ Mn), 2020-2033
- 3.4.1. North America
- 3.4.2. Europe
- 3.4.3. Asia Pacific
- 3.4.4. Latin America
- 3.4.5. Middle East & Africa
4. North America PD-L1 Biomarker Testing Market Outlook, 2020-2033
- 4.1. North America PD-L1 Biomarker Testing Market Outlook, by Test Type, Value (US$ Mn), 2020-2033
- 4.1.1. Non-Small Cell Lung Cancer NSCLC
- 4.1.2. Melanoma
- 4.1.3. Renal Cell Carcinoma
- 4.1.4. Gastrointestinal Tract Malignancy
- 4.1.5. Haematological Malignancies
- 4.1.6. Ovarian Cancer
- 4.1.7. Other
- 4.2. North America PD-L1 Biomarker Testing Market Outlook, by Technology, Value (US$ Mn), 2020-2033
- 4.2.1. Immunohistochemistry IHC Based Testing
- 4.2.2. Polymerase Chain Reaction Based Testing
- 4.2.3. Next Generation Sequencing Based Testing
- 4.2.4. Others
- 4.3. North America PD-L1 Biomarker Testing Market Outlook, by Sample Type, Value (US$ Mn), 2020-2033
- 4.3.1. Tissue Biopsy Samples
- 4.3.2. Blood Based Liquid Biopsy
- 4.4. North America PD-L1 Biomarker Testing Market Outlook, by Country, Value (US$ Mn), 2020-2033
- 4.4.1. U.S. PD-L1 Biomarker Testing Market Outlook, by Test Type, 2020-2033
- 4.4.2. U.S. PD-L1 Biomarker Testing Market Outlook, by Technology, 2020-2033
- 4.4.3. U.S. PD-L1 Biomarker Testing Market Outlook, by Sample Type, 2020-2033
- 4.4.4. Canada PD-L1 Biomarker Testing Market Outlook, by Test Type, 2020-2033
- 4.4.5. Canada PD-L1 Biomarker Testing Market Outlook, by Technology, 2020-2033
- 4.4.6. Canada PD-L1 Biomarker Testing Market Outlook, by Sample Type, 2020-2033
- 4.5. BPS Analysis/Market Attractiveness Analysis
5. Europe PD-L1 Biomarker Testing Market Outlook, 2020-2033
- 5.1. Europe PD-L1 Biomarker Testing Market Outlook, by Test Type, Value (US$ Mn), 2020-2033
- 5.1.1. Non-Small Cell Lung Cancer NSCLC
- 5.1.2. Melanoma
- 5.1.3. Renal Cell Carcinoma
- 5.1.4. Gastrointestinal Tract Malignancy
- 5.1.5. Haematological Malignancies
- 5.1.6. Ovarian Cancer
- 5.1.7. Other
- 5.2. Europe PD-L1 Biomarker Testing Market Outlook, by Technology, Value (US$ Mn), 2020-2033
- 5.2.1. Immunohistochemistry IHC Based Testing
- 5.2.2. Polymerase Chain Reaction Based Testing
- 5.2.3. Next Generation Sequencing Based Testing
- 5.2.4. Others
- 5.3. Europe PD-L1 Biomarker Testing Market Outlook, by Sample Type, Value (US$ Mn), 2020-2033
- 5.3.1. Tissue Biopsy Samples
- 5.3.2. Blood Based Liquid Biopsy
- 5.4. Europe PD-L1 Biomarker Testing Market Outlook, by Country, Value (US$ Mn), 2020-2033
- 5.4.1. Germany PD-L1 Biomarker Testing Market Outlook, by Test Type, 2020-2033
- 5.4.2. Germany PD-L1 Biomarker Testing Market Outlook, by Technology, 2020-2033
- 5.4.3. Germany PD-L1 Biomarker Testing Market Outlook, by Sample Type, 2020-2033
- 5.4.4. Italy PD-L1 Biomarker Testing Market Outlook, by Test Type, 2020-2033
- 5.4.5. Italy PD-L1 Biomarker Testing Market Outlook, by Technology, 2020-2033
- 5.4.6. Italy PD-L1 Biomarker Testing Market Outlook, by Sample Type, 2020-2033
- 5.4.7. France PD-L1 Biomarker Testing Market Outlook, by Test Type, 2020-2033
- 5.4.8. France PD-L1 Biomarker Testing Market Outlook, by Technology, 2020-2033
- 5.4.9. France PD-L1 Biomarker Testing Market Outlook, by Sample Type, 2020-2033
- 5.4.10. U.K. PD-L1 Biomarker Testing Market Outlook, by Test Type, 2020-2033
- 5.4.11. U.K. PD-L1 Biomarker Testing Market Outlook, by Technology, 2020-2033
- 5.4.12. U.K. PD-L1 Biomarker Testing Market Outlook, by Sample Type, 2020-2033
- 5.4.13. Spain PD-L1 Biomarker Testing Market Outlook, by Test Type, 2020-2033
- 5.4.14. Spain PD-L1 Biomarker Testing Market Outlook, by Technology, 2020-2033
- 5.4.15. Spain PD-L1 Biomarker Testing Market Outlook, by Sample Type, 2020-2033
- 5.4.16. Russia PD-L1 Biomarker Testing Market Outlook, by Test Type, 2020-2033
- 5.4.17. Russia PD-L1 Biomarker Testing Market Outlook, by Technology, 2020-2033
- 5.4.18. Russia PD-L1 Biomarker Testing Market Outlook, by Sample Type, 2020-2033
- 5.4.19. Rest of Europe PD-L1 Biomarker Testing Market Outlook, by Test Type, 2020-2033
- 5.4.20. Rest of Europe PD-L1 Biomarker Testing Market Outlook, by Technology, 2020-2033
- 5.4.21. Rest of Europe PD-L1 Biomarker Testing Market Outlook, by Sample Type, 2020-2033
- 5.5. BPS Analysis/Market Attractiveness Analysis
6. Asia Pacific PD-L1 Biomarker Testing Market Outlook, 2020-2033
- 6.1. Asia Pacific PD-L1 Biomarker Testing Market Outlook, by Test Type, Value (US$ Mn), 2020-2033
- 6.1.1. Non-Small Cell Lung Cancer NSCLC
- 6.1.2. Melanoma
- 6.1.3. Renal Cell Carcinoma
- 6.1.4. Gastrointestinal Tract Malignancy
- 6.1.5. Haematological Malignancies
- 6.1.6. Ovarian Cancer
- 6.1.7. Other
- 6.2. Asia Pacific PD-L1 Biomarker Testing Market Outlook, by Technology, Value (US$ Mn), 2020-2033
- 6.2.1. Immunohistochemistry IHC Based Testing
- 6.2.2. Polymerase Chain Reaction Based Testing
- 6.2.3. Next Generation Sequencing Based Testing
- 6.2.4. Others
- 6.3. Asia Pacific PD-L1 Biomarker Testing Market Outlook, by Sample Type, Value (US$ Mn), 2020-2033
- 6.3.1. Tissue Biopsy Samples
- 6.3.2. Blood Based Liquid Biopsy
- 6.4. Asia Pacific PD-L1 Biomarker Testing Market Outlook, by Country, Value (US$ Mn), 2020-2033
- 6.4.1. China PD-L1 Biomarker Testing Market Outlook, by Test Type, 2020-2033
- 6.4.2. China PD-L1 Biomarker Testing Market Outlook, by Technology, 2020-2033
- 6.4.3. China PD-L1 Biomarker Testing Market Outlook, by Sample Type, 2020-2033
- 6.4.4. Japan PD-L1 Biomarker Testing Market Outlook, by Test Type, 2020-2033
- 6.4.5. Japan PD-L1 Biomarker Testing Market Outlook, by Technology, 2020-2033
- 6.4.6. Japan PD-L1 Biomarker Testing Market Outlook, by Sample Type, 2020-2033
- 6.4.7. South Korea PD-L1 Biomarker Testing Market Outlook, by Test Type, 2020-2033
- 6.4.8. South Korea PD-L1 Biomarker Testing Market Outlook, by Technology, 2020-2033
- 6.4.9. South Korea PD-L1 Biomarker Testing Market Outlook, by Sample Type, 2020-2033
- 6.4.10. India PD-L1 Biomarker Testing Market Outlook, by Test Type, 2020-2033
- 6.4.11. India PD-L1 Biomarker Testing Market Outlook, by Technology, 2020-2033
- 6.4.12. India PD-L1 Biomarker Testing Market Outlook, by Sample Type, 2020-2033
- 6.4.13. Southeast Asia PD-L1 Biomarker Testing Market Outlook, by Test Type, 2020-2033
- 6.4.14. Southeast Asia PD-L1 Biomarker Testing Market Outlook, by Technology, 2020-2033
- 6.4.15. Southeast Asia PD-L1 Biomarker Testing Market Outlook, by Sample Type, 2020-2033
- 6.4.16. Rest of SAO PD-L1 Biomarker Testing Market Outlook, by Test Type, 2020-2033
- 6.4.17. Rest of SAO PD-L1 Biomarker Testing Market Outlook, by Technology, 2020-2033
- 6.4.18. Rest of SAO PD-L1 Biomarker Testing Market Outlook, by Sample Type, 2020-2033
- 6.5. BPS Analysis/Market Attractiveness Analysis
7. Latin America PD-L1 Biomarker Testing Market Outlook, 2020-2033
- 7.1. Latin America PD-L1 Biomarker Testing Market Outlook, by Test Type, Value (US$ Mn), 2020-2033
- 7.1.1. Non-Small Cell Lung Cancer NSCLC
- 7.1.2. Melanoma
- 7.1.3. Renal Cell Carcinoma
- 7.1.4. Gastrointestinal Tract Malignancy
- 7.1.5. Haematological Malignancies
- 7.1.6. Ovarian Cancer
- 7.1.7. Other
- 7.2. Latin America PD-L1 Biomarker Testing Market Outlook, by Technology, Value (US$ Mn), 2020-2033
- 7.2.1. Immunohistochemistry IHC Based Testing
- 7.2.2. Polymerase Chain Reaction Based Testing
- 7.2.3. Next Generation Sequencing Based Testing
- 7.2.4. Others
- 7.3. Latin America PD-L1 Biomarker Testing Market Outlook, by Sample Type, Value (US$ Mn), 2020-2033
- 7.3.1. Tissue Biopsy Samples
- 7.3.2. Blood Based Liquid Biopsy
- 7.4. Latin America PD-L1 Biomarker Testing Market Outlook, by Country, Value (US$ Mn), 2020-2033
- 7.4.1. Brazil PD-L1 Biomarker Testing Market Outlook, by Test Type, 2020-2033
- 7.4.2. Brazil PD-L1 Biomarker Testing Market Outlook, by Technology, 2020-2033
- 7.4.3. Brazil PD-L1 Biomarker Testing Market Outlook, by Sample Type, 2020-2033
- 7.4.4. Mexico PD-L1 Biomarker Testing Market Outlook, by Test Type, 2020-2033
- 7.4.5. Mexico PD-L1 Biomarker Testing Market Outlook, by Technology, 2020-2033
- 7.4.6. Mexico PD-L1 Biomarker Testing Market Outlook, by Sample Type, 2020-2033
- 7.4.7. Argentina PD-L1 Biomarker Testing Market Outlook, by Test Type, 2020-2033
- 7.4.8. Argentina PD-L1 Biomarker Testing Market Outlook, by Technology, 2020-2033
- 7.4.9. Argentina PD-L1 Biomarker Testing Market Outlook, by Sample Type, 2020-2033
- 7.4.10. Rest of LATAM PD-L1 Biomarker Testing Market Outlook, by Test Type, 2020-2033
- 7.4.11. Rest of LATAM PD-L1 Biomarker Testing Market Outlook, by Technology, 2020-2033
- 7.4.12. Rest of LATAM PD-L1 Biomarker Testing Market Outlook, by Sample Type, 2020-2033
- 7.5. BPS Analysis/Market Attractiveness Analysis
8. Middle East & Africa PD-L1 Biomarker Testing Market Outlook, 2020-2033
- 8.1. Middle East & Africa PD-L1 Biomarker Testing Market Outlook, by Test Type, Value (US$ Mn), 2020-2033
- 8.1.1. Non-Small Cell Lung Cancer NSCLC
- 8.1.2. Melanoma
- 8.1.3. Renal Cell Carcinoma
- 8.1.4. Gastrointestinal Tract Malignancy
- 8.1.5. Haematological Malignancies
- 8.1.6. Ovarian Cancer
- 8.1.7. Other
- 8.2. Middle East & Africa PD-L1 Biomarker Testing Market Outlook, by Technology, Value (US$ Mn), 2020-2033
- 8.2.1. Immunohistochemistry IHC Based Testing
- 8.2.2. Polymerase Chain Reaction Based Testing
- 8.2.3. Next Generation Sequencing Based Testing
- 8.2.4. Others
- 8.3. Middle East & Africa PD-L1 Biomarker Testing Market Outlook, by Sample Type, Value (US$ Mn), 2020-2033
- 8.3.1. Tissue Biopsy Samples
- 8.3.2. Blood Based Liquid Biopsy
- 8.4. Middle East & Africa PD-L1 Biomarker Testing Market Outlook, by Country, Value (US$ Mn), 2020-2033
- 8.4.1. GCC PD-L1 Biomarker Testing Market Outlook, by Test Type, 2020-2033
- 8.4.2. GCC PD-L1 Biomarker Testing Market Outlook, by Technology, 2020-2033
- 8.4.3. GCC PD-L1 Biomarker Testing Market Outlook, by Sample Type, 2020-2033
- 8.4.4. South Africa PD-L1 Biomarker Testing Market Outlook, by Test Type, 2020-2033
- 8.4.5. South Africa PD-L1 Biomarker Testing Market Outlook, by Technology, 2020-2033
- 8.4.6. South Africa PD-L1 Biomarker Testing Market Outlook, by Sample Type, 2020-2033
- 8.4.7. Egypt PD-L1 Biomarker Testing Market Outlook, by Test Type, 2020-2033
- 8.4.8. Egypt PD-L1 Biomarker Testing Market Outlook, by Technology, 2020-2033
- 8.4.9. Egypt PD-L1 Biomarker Testing Market Outlook, by Sample Type, 2020-2033
- 8.4.10. Nigeria PD-L1 Biomarker Testing Market Outlook, by Test Type, 2020-2033
- 8.4.11. Nigeria PD-L1 Biomarker Testing Market Outlook, by Technology, 2020-2033
- 8.4.12. Nigeria PD-L1 Biomarker Testing Market Outlook, by Sample Type, 2020-2033
- 8.4.13. Rest of Middle East PD-L1 Biomarker Testing Market Outlook, by Test Type, 2020-2033
- 8.4.14. Rest of Middle East PD-L1 Biomarker Testing Market Outlook, by Technology, 2020-2033
- 8.4.15. Rest of Middle East PD-L1 Biomarker Testing Market Outlook, by Sample Type, 2020-2033
- 8.5. BPS Analysis/Market Attractiveness Analysis
9. Competitive Landscape
- 9.1. Company Vs Segment Heatmap
- 9.2. Company Market Share Analysis, 2025
- 9.3. Competitive Dashboard
- 9.4. Company Profiles
- 9.4.1. Hoffmann-La Roche Ltd.
- 9.4.1.1. Company Overview
- 9.4.1.2. Product Portfolio
- 9.4.1.3. Financial Overview
- 9.4.1.4. Business Strategies and Developments
- 9.4.2. Agilent Technologies, Inc.
- 9.4.3. Merck and Co., Inc.
- 9.4.4. Bristol-Myers Squibb
- 9.4.5. Thermo Fisher Scientific
- 9.4.6. Abcam plc.
- 9.4.7. Abbott Laboratories
- 9.4.1. Hoffmann-La Roche Ltd.
10. Appendix
- 10.1. Research Methodology
- 10.2. Report Assumptions
- 10.3. Acronyms and Abbreviations
